<p>隨着全球市場應對貿易政策和通脹趨勢的複雜性，投資者密切關注這些因素對股票表現的影響。美國股票在關税不確定性中表現出韌性，而歐洲指數因通脹預期緩解而受到提振，股息股票繼續成為那些尋求在波動市場環境中獲得穩定收入的投資者的吸引選項。</p>
<h3>全球十大股息股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股息收益率</strong></td>
<td><strong>股息評級</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大東信託建設有限公司 (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>安聯 (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大慶化學 (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC 控股 (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>山田工業 (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>同志社有限公司 (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>學究社有限公司 (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>沃州銀行 (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>日本優秀 (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球十大股息股票篩選器的 1552 只股票的完整列表。</p>
<p>我們將查看篩選工具中一些最佳選擇。</p>
<h2>ORION 控股 (KOSE:A001800)</h2>
<p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ORION 控股公司是一家在韓國、中國及國際上製造和銷售糖果的公司，市值為₩1.12 萬億。</p>
<p><strong>運營：</strong> ORION 控股公司的收入部分包括糖果業務₩3.90 萬億，房東業務₩66.56 億，以及視頻業務₩41.64 億。</p>
<p><strong>股息收益率：</strong> 3.6%</p>
<p>ORION 控股的股息支付得到了收益和現金流的良好支持，派息比率為 31.5%，現金派息比率為 12.6%。然而，過去十年股息波動較大，儘管在此期間支付有所增長，但顯示出不可靠性。最近的財報顯示業績波動，2025 年第一季度淨收入較去年下降，突顯出維持穩定股息的潛在挑戰。</p>
<ul>
<li>點擊這裏瞭解 ORION 控股的細微差別，查看我們的詳細分析股息報告。</li>
<li>我們的估值報告顯示 ORION 控股可能被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 KOSE:A001800 股息歷史</p>
<h2>桂林三金藥業 (SZSE:002275)</h2>
<p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 桂林三金藥業有限公司專注於中國傳統中藥和天然藥物的研究、生產和銷售，市值為 CN¥86.2 億。</p>
<p><strong>運營：</strong> 桂林三金藥業有限公司主要通過研究、生產和銷售中國傳統中藥和天然藥物來產生收入。</p>
<p><strong>股息收益率：</strong> 3.7%</p>
<p>桂林三金藥業的股息得到了收益和現金流的良好支持，派息比率分別為 66.6% 和 67.9%。儘管在中國是頂級股息支付者之一，但其過去十年的記錄不穩定，支付沒有增長。最近批准的每 10 股派發 CNY 3.50 的股息突顯了儘管過去波動和大額一次性項目影響財務結果，仍然致力於回報。</p>
<ul>
<li>通過我們的綜合股息報告瞭解桂林三金藥業的複雜性。</li>
<li>我們精心準備的桂林三金藥業估值報告暗示其股價可能低於預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 SZSE:002275 股息歷史</p>
<h2>青島百合醫療 (SZSE:301015)</h2>
<p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 青島百合醫療有限公司從事藥品的研究、開發、生產和銷售，市值為 CN¥98.4 億。</p>
<p><strong>運營：</strong> 青島百合醫療有限公司通過藥品的研究、開發、生產和銷售來產生收入。</p>
<p><strong>股息收益率：</strong> 3.8%</p>
<p>青島百合醫療的股息支付得到了收益和現金流的良好支持，派息比率分別為 67.6% 和 68.2%。儘管該公司僅支付了三年的股息，但每 10 股派發 CNY 7.62 的股息反映了對股東的穩定承諾，使其成為中國頂級股息支付者之一。儘管最近的收益壓力使 2025 年第一季度淨收入下降至 CNY 8500 萬，但由於強勁的覆蓋指標，股息仍然可持續。</p>
<ul>
<li>點擊探索我們在青島百合醫療股息報告中的詳細發現。</li>
<li>我們編制的估值報告表明青島百合醫療的當前價格可能相當適中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 SZSE:301015 股息歷史</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>在這裏瀏覽 1552 只全球頂級股息股票的完整清單。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取任何新警告信號的提醒。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用。</li>
</ul>
<h2>準備好不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，得到分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

桂林三金

Orion集團控股

<p>隨着全球市場面臨貿易政策複雜性和通脹趨勢，股息股票因其穩定的收入而仍然具有吸引力。全球前十大股息股票包括 en-japan、大東信託建設、安聯等，收益率範圍從 4.04% 到 4.93%。像 ORION 集團控股和桂林三金這樣的公司顯示出強勁的股息覆蓋率，但也經歷了波動。青島百合醫療儘管近期面臨盈利壓力，但仍保持可持續的股息。此分析強調了在波動市場中股息股票的重要性，為尋求可靠回報的投資者提供了見解</p>

<p>As global markets navigate the complexities of trade policies and inflation trends, investors are keenly observing the impact of these factors on equity performance. With U.S. stocks showing resilience amid tariff uncertainties and European indices buoyed by easing inflation expectations, dividend stocks continue to be an attractive option for those seeking steady income in a fluctuating market environment.</p>
<div class="lb-trans"><p>隨着全球市場應對貿易政策和通脹趨勢的複雜性，投資者密切關注這些因素對股票表現的影響。美國股票在關税不確定性中表現出韌性，而歐洲指數因通脹預期緩解而受到提振，股息股票繼續成為那些尋求在波動市場環境中獲得穩定收入的投資者的吸引選項。</p>
</div><h3>Top 10 Dividend Stocks Globally</h3>
<div class="lb-trans"><h3>全球十大股息股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Dividend Yield</strong></td>
<td><strong>Dividend Rating</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daito Trust ConstructionLtd (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Allianz (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daicel (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC Holdings (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Yamato Kogyo (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>DoshishaLtd (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>GakkyushaLtd (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Banque Cantonale Vaudoise (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Japan Excellent (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股息收益率</strong></td>
<td><strong>股息評級</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大東信託建設有限公司 (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>安聯 (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大慶化學 (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC 控股 (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>山田工業 (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>同志社有限公司 (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>學究社有限公司 (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>沃州銀行 (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>日本優秀 (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1552 stocks from our Top Global Dividend Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球十大股息股票篩選器的 1552 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中一些最佳選擇。</p>
</div><h2>ORION Holdings (KOSE:A001800)</h2>
<div class="lb-trans"><h2>ORION 控股 (KOSE:A001800)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ORION Holdings Corp. is a company that manufactures and sells confectioneries in South Korea, China, and internationally, with a market cap of ₩1.12 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ORION 控股公司是一家在韓國、中國及國際上製造和銷售糖果的公司，市值為₩1.12 萬億。</p>
</div><p><strong>Operations:</strong> ORION Holdings Corp.'s revenue segments include Confectionery at ₩3.90 trillion, Landlord at ₩66.56 billion, and Video at ₩41.64 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> ORION 控股公司的收入部分包括糖果業務₩3.90 萬億，房東業務₩66.56 億，以及視頻業務₩41.64 億。</p>
</div><p><strong>Dividend Yield:</strong> 3.6%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.6%</p>
</div><p>ORION Holdings' dividend payments are well-covered by both earnings and cash flows, with a payout ratio of 31.5% and a cash payout ratio of 12.6%. However, the dividends have been volatile over the past decade, showing unreliability despite growth in payouts during this period. Recent earnings reports indicate fluctuating performance, with Q1 2025 net income decreasing compared to the previous year, highlighting potential challenges for maintaining stable dividends.</p>
<div class="lb-trans"><p>ORION 控股的股息支付得到了收益和現金流的良好支持，派息比率為 31.5%，現金派息比率為 12.6%。然而，過去十年股息波動較大，儘管在此期間支付有所增長，但顯示出不可靠性。最近的財報顯示業績波動，2025 年第一季度淨收入較去年下降，突顯出維持穩定股息的潛在挑戰。</p>
</div><ul>
<li>Click here to discover the nuances of ORION Holdings with our detailed analytical dividend report.</li>
<li>Our valuation report here indicates ORION Holdings may be undervalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 ORION 控股的細微差別，查看我們的詳細分析股息報告。</li>
<li>我們的估值報告顯示 ORION 控股可能被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend"/></p>
<p>KOSE:A001800 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 KOSE:A001800 股息歷史</p>
</div><h2>Guilin Sanjin Pharmaceutical (SZSE:002275)</h2>
<div class="lb-trans"><h2>桂林三金藥業 (SZSE:002275)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Guilin Sanjin Pharmaceutical Co., Ltd. focuses on the research, production, and sale of traditional Chinese and natural medicines in China, with a market cap of CN¥8.62 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 桂林三金藥業有限公司專注於中國傳統中藥和天然藥物的研究、生產和銷售，市值為 CN¥86.2 億。</p>
</div><p><strong>Operations:</strong> Guilin Sanjin Pharmaceutical Co., Ltd. generates its revenue primarily through the research, production, and sale of traditional Chinese and natural medicines in China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 桂林三金藥業有限公司主要通過研究、生產和銷售中國傳統中藥和天然藥物來產生收入。</p>
</div><p><strong>Dividend Yield:</strong> 3.7%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.7%</p>
</div><p>Guilin Sanjin Pharmaceutical's dividend is well-covered by earnings and cash flows, with payout ratios of 66.6% and 67.9%, respectively. Despite being among the top dividend payers in China, its track record has been unstable over the past decade, with no growth in payments. Recent approval of a CNY 3.50 per 10 shares dividend highlights commitment to returns despite past volatility and large one-off items affecting financial results.</p>
<div class="lb-trans"><p>桂林三金藥業的股息得到了收益和現金流的良好支持，派息比率分別為 66.6% 和 67.9%。儘管在中國是頂級股息支付者之一，但其過去十年的記錄不穩定，支付沒有增長。最近批准的每 10 股派發 CNY 3.50 的股息突顯了儘管過去波動和大額一次性項目影響財務結果，仍然致力於回報。</p>
</div><ul>
<li>Navigate through the intricacies of Guilin Sanjin Pharmaceutical with our comprehensive dividend report here.</li>
<li>Our expertly prepared valuation report Guilin Sanjin Pharmaceutical implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合股息報告瞭解桂林三金藥業的複雜性。</li>
<li>我們精心準備的桂林三金藥業估值報告暗示其股價可能低於預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend"/></p>
<p>SZSE:002275 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SZSE:002275 股息歷史</p>
</div><h2>Qingdao Baheal Medical (SZSE:301015)</h2>
<div class="lb-trans"><h2>青島百合醫療 (SZSE:301015)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Qingdao Baheal Medical INC. is involved in the research, development, production, and sale of pharmaceutical products and has a market cap of CN¥9.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青島百合醫療有限公司從事藥品的研究、開發、生產和銷售，市值為 CN¥98.4 億。</p>
</div><p><strong>Operations:</strong> Qingdao Baheal Medical INC. generates its revenue through the research, development, production, and sale of pharmaceutical products.</p>
<div class="lb-trans"><p><strong>運營：</strong> 青島百合醫療有限公司通過藥品的研究、開發、生產和銷售來產生收入。</p>
</div><p><strong>Dividend Yield:</strong> 3.8%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.8%</p>
</div><p>Qingdao Baheal Medical's dividend payments are well-supported by earnings and cash flows, with payout ratios of 67.6% and 68.2%, respectively. Although the company has only paid dividends for three years, its CNY 7.62 per 10 shares dividend reflects a stable commitment to shareholders, placing it among the top dividend payers in China. Despite recent earnings pressure with net income declining to CNY 85 million in Q1 2025, dividends remain sustainable due to strong coverage metrics.</p>
<div class="lb-trans"><p>青島百合醫療的股息支付得到了收益和現金流的良好支持，派息比率分別為 67.6% 和 68.2%。儘管該公司僅支付了三年的股息，但每 10 股派發 CNY 7.62 的股息反映了對股東的穩定承諾，使其成為中國頂級股息支付者之一。儘管最近的收益壓力使 2025 年第一季度淨收入下降至 CNY 8500 萬，但由於強勁的覆蓋指標，股息仍然可持續。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Qingdao Baheal Medical's dividend report.</li>
<li>The valuation report we've compiled suggests that Qingdao Baheal Medical's current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在青島百合醫療股息報告中的詳細發現。</li>
<li>我們編制的估值報告表明青島百合醫療的當前價格可能相當適中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend"/></p>
<p>SZSE:301015 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SZSE:301015 股息歷史</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Navigate through the entire inventory of 1552 Top Global Dividend Stocks here.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽 1552 只全球頂級股息股票的完整清單。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取任何新警告信號的提醒。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，得到分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

2025 年 6 月值得關注的全球股息股票